{'fraction_non_alphanumeric': 0.03597122302158273, 'fraction_numerical': 0.014388489208633094, 'mean_word_length': 4.903030303030303, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Effect of liposome-C-erbB2 antisense oligodeoxynucleotides on human ovarian cancer cells].

OBJECTIVE
To explore the effects of liposome-C-erbB2 antisense phosphorothioate oligo deoxynucleotides(S-ODNs) on C-erbB2 protooncogene expression and cell proliferation in human ovarian cancer cells.


METHODS
The effects on C-erbB2 protooncogene expression, cell proliferation and cell cycle in human ovarian cancer cells were studied by flow cytometry and 3H-thymidine incorporation.


RESULTS
Liposome-C-erbB2 S-ODNs could reduce C-erbB2 expression and inhibit cell proliferation in human ovarian cancer cells; the effectiveness of liposome-C-erbB2 S-ODNs on the expression of C-erbB2 was much higher than that of C-erbB2 S-ODNs, about 40 times.


CONCLUSIONS
The data in this study suggest that antisense therapy is an useful method of gene therapy in ovarian cancer. The effectiveness of C-erbB2 S-ODNs could be greatly increased by C-erbB2 S-ODNs encapsulated in liposomes.